The consequences of MDMA use are not easily disentangled from other drug use or lifestyle factors.
Brain April 30, 2026
The effects of MDMA use are difficult to separate from the influence of other drugs and lifestyle factors.
11 results for "Meta-analysis: what did research on mdma find in april 2026?"
Topics
The Ecstasy of Gold in Neurodiversity: Focus on the Use of Psychedelics in Autism Spectrum Disorder
Preprints.org April 29, 2026 Stefano Marini, Domenico de Berardis preprint
Psychedelic drugs, both natural and synthetic, act on serotonin receptors and may enhance cognition, brain connectivity, neuroplasticity, and neuronal regeneration. Autism spectrum disorder involves social communication difficulties and repetitive behaviors, with no approved drugs for core symptoms. Current treatments for co-occurring conditions often have uncertain efficacy and tolerability. This review reports studies indicating that psychedelics could be therapeutically useful for some autism-related symptoms, suggesting a potential role in treatment.
Fusing Specialized Surveys of Rare Populations to Larger Surveys for Generalized Inference: Cross-Sectional Survey Study.
Journal of medical Internet research April 27, 2026 Karilynn M Rockhill, Elizabeth A Bemis, Nicole Schow et al. 2 citations
Combining a large representative survey with a smaller survey focused on psychedelic drugs can produce generalizable estimates of rare behaviors like drug use without adding burdensome questions to the big survey. Researchers used calibration weighting to transport estimates from a psychedelic-enriched survey (two waves, total over 4,300 adults) to a representative anchor survey (two waves, total over 57,000 adults). The method showed good internal consistency, with transport biases under 0.4 percentage points for demographics, health, and substance use. External validity improved for health and substance use estimates after fusion. Using the fused data, recreational use of psilocybin (92.9%), LSD (93.2%), and MDMA (93.3%) was far more common than medical use (30.9%, 26.4%, and 21.1%, respectively). This approach expands surveillance epidemiology for rare behaviors.
Protective effects of vitamin E and quercetin against MDMA-induced cardiac and hematological dysfunction in male wistar rats.
Pflugers Archiv : European journal of physiology April 23, 2026 Ayodeji Folorunsho Ajayi, David Tolulope Oluwole, Moses Agbomhere Hamed et al.
In adult male Wistar rats, the recreational drug MDMA (ecstasy) caused heart damage, oxidative stress, inflammation, abnormal blood lipids, and disrupted blood cell counts. The antioxidants quercetin and vitamin E, given separately, each reduced these harmful effects. When given together, quercetin and vitamin E provided the greatest protection, nearly restoring normal heart tissue, blood chemistry, and blood cell levels. Neither antioxidant alone altered normal rats' baseline measurements. The combined treatment suggests a potential approach for mitigating MDMA-related heart and blood toxicity.
Substance use predictors of arrest and self-reported criminal behavior in the United States: The role of psychedelics and rarely used drugs
Journal of Psychopharmacology April 16, 2026 Jesse J. Norris 1 citation
Using data from a large US survey (2014–2023, 544,740 respondents), the study examined links between rarely used drugs and criminal behavior. Phencyclidine (PCP) use was strongly associated with arrest for serious violent offenses, assault, and sex offenses, and with attacking three or more people. Gamma-hydroxybutyrate (GHB) was linked to arrest for several offenses. Among psychedelics, psilocybin was associated with reduced odds of several offenses, while DMT/AMT/Foxy and peyote were linked to increased odds. LSD and Salvia divinorum showed mixed associations. Protective effects of psychedelics were largely absent for minors and were stronger for whites than for minorities. The mixed findings highlight the need for further research on causal connections between psychedelics and crime.
Effects of MDMA treatment and cessation on sexual behaviour and testicular functions in male sprague-dawley rats.
BMC pharmacology & toxicology April 11, 2026 O O Obembe, E T George, R A Mustapha et al.
Chronic MDMA exposure in male rats initially increased sexual behaviors such as mounting, intromission, and ejaculation, but these declined during withdrawal. Sperm count and motility decreased after MDMA treatment, with partial recovery after a 30-day drug-free period. Markers of oxidative stress and pro-inflammatory cytokines increased in both serum and testes, while antioxidant enzymes decreased. MDMA also suppressed luteinizing hormone, follicle-stimulating hormone, and testosterone levels. Testicular histology showed reduced spermatid populations, which improved after cessation. Partial recovery after stopping MDMA suggests potential long-term reproductive risks.
Subjective and neurocognitive profiling of clinical doses of 3,4-methylenedioxymethamphetamine (MDMA) in healthy volunteers: implications for therapeutic use
Molecular Psychiatry April 8, 2026 Johannes G. Ramaekers, Kim P. C. Kuypers, Franz X. Vollenweider 1 citation
MDMA, originally developed for military purposes and later used recreationally, is now being tested in clinical trials for PTSD. A narrative review of placebo-controlled single-dose studies in healthy volunteers found that 75-125 mg of MDMA acutely enhances mood, empathy, trust, and arousal while transiently impairing memory encoding through increased serotonin signaling. Motor coordination and cognitive flexibility decline modestly, but inhibitory control and executive function remain largely intact. Post-acutely, fatigue and low mood may occur. These effects may support trauma processing by facilitating fear extinction and disrupting negative memory reconsolidation, though they also complicate trial design by compromising blinding and inflating expectancy.
The impact of antidepressant use on MDMA fatalities: A matched case-control study using a post-mortem database.
Journal of psychopharmacology (Oxford, England) April 6, 2026 Kirsten L Rock, Paul Rees, David Morgan et al.
MDMA is being studied as a treatment for PTSD, but many patients already take antidepressants. This retrospective case-control study used a national drug-death database to examine whether antidepressant use is linked to MDMA-related deaths. Among 1328 MDMA-positive deaths and 5312 matched controls, post-mortem detection of antidepressants was associated with lower odds of MDMA fatality compared to other drug-related deaths (adjusted odds ratio 0.595, 95% CI 0.491-0.722). However, when analyzing prescribed antidepressants, no significant association was found (adjusted odds ratio 0.838, 95% CI 0.688-1.021). The findings suggest an inverse association between antidepressant use and MDMA fatality, but the relationship is not straightforward.
Ecstasy (MDMA) for social anxiety in autism: a specialized application of empathogen therapy
Annals of Medicine and Surgery April 6, 2026 Mahnoor Sheikh, Zaibunnisa Bilal, Syeda Habiba Fatima et al.
Autistic adults often experience social anxiety that persists despite behavioral interventions. A randomized, double-blind, placebo-controlled pilot trial found that MDMA-assisted psychotherapy significantly reduced social fear and anxiety in autistic adults. MDMA appears to enhance prosocial behaviors and empathy, partly by reducing amygdala reactivity and releasing oxytocin. Common acute side effects include fatigue, reduced appetite, jaw clenching, and sweating; cardiovascular effects such as transient hypertension and tachycardia occur, contraindicating use in patients with heart conditions. Delayed effects can include transient anxiety and depressed mood. The therapy was well-tolerated under controlled clinical settings, but small sample sizes and lack of long-term follow-up limit conclusions. Larger trials are needed before MDMA can be considered for autism-related therapies.
3,4-Methylenedioxymethamphetamine: From Dangerous Party Drug to Potential Therapeutic Agent
Quality in Sport April 5, 2026 Magdalena Ostaszewska, Milena Majchrzyk, Damian Zienkiewicz et al.
MDMA, a stimulant drug used recreationally for its mood-enhancing effects, can cause cognitive dysfunction, emotional dysregulation, and life-threatening hyperthermia with prolonged misuse. Despite these dangers, research indicates MDMA may become a valuable therapeutic adjunct for treating psychiatric conditions including PTSD, alcohol dependence, depression, and anxiety, and may also benefit athletic populations. Existing studies are limited by small sample sizes, underscoring the need for further large-scale research to confirm these findings.
Market approval and the right to health: a human rights perspective on MDMA-assisted therapy
JME Practical Bioethics April 1, 2026 Christoph Bublitz
The FDA's 2024 rejection of MDMA-assisted therapy sparked debate about ethics in drug regulation. This paper examines that debate through a human rights lens, particularly the right to health. It argues that drug approval decisions must consider the interdependent relationships among patients, regulators, pharmaceutical sponsors, and the public. While acknowledging the ethical concerns raised, the analysis suggests that typical arguments for rejection insufficiently considered the costs to patients who would have benefited. The paper also argues that a human rights-based approach supports expanding unlicensed use programs under certain conditions and that evidentiary standards for approval may need reconsideration if double-blind trials are practically infeasible in psychedelic research.